Trials / Completed
CompletedNCT00195208
Study Comparing a Pantoprazole Formulation to the Currently Marketed Tablet for GERD and Erosive Esophagitis
A Randomized, 2-Period, Crossover, Pharmacodynamic Comparability Study Comparing A Pantoprazole Spheroid Formulation to the Currently Marketed Tablet Formulation in Subjects With GERD and a History of Erosive Esophagitis.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 97 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to demonstrate pharmacodynamic comparability between the pantoprazole spheroid formulation and the marketed tablet formulation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pantoprazole for approximately 9 weeks |
Timeline
- Start date
- 2005-06-01
- Primary completion
- 2005-11-01
- Completion
- 2005-11-01
- First posted
- 2005-09-19
- Last updated
- 2013-02-08
Locations
9 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00195208. Inclusion in this directory is not an endorsement.